Abstract
Background
C‐reactive protein (CRP) and myeloperoxidase (MPO) are involved in the pathogenesis of atherosclerosis, mainly during periods of instabilization. This study aims to test the hypothesis that patients with acute coronary syndrome (ACS) maintain a persistent inflammatory state, and that this is associated with long‐term mortality.
Hypothesis
We hypothesized that serum C‐reactive protein and myeloperoxidase collected at the index event and later, could add to the prognostic information in patients with ACS.
Methods
In a prospective cohort of 115 consecutive patients with ACS, myeloperoxidase and C‐reactive protein were measured at admission and 2 y later. Patients were followed‐up for the occurrence of cardiac death and other major cardiac events.
Results
Levels of CRP decreased from 26 ± 34 mg/L in the acute phase to 6 ± 8 mg/L in the chronic phase (p < 0.001), and MPO levels decreased from 86 ± 43 pM to 27 ± 32 pM (p < 0.001). After 29 ± 12 mo, 27% patients died, 39% had new episode of ACS, and 30% underwent revascularization procedures. Initial CRP levels above 10 mg/L were associated with higher long‐term mortality (hazard ratio [HR]: 2.43; 95% confidence interval [CI]: 0.98 to 6.07; p = 0.048). MPO levels were not associated with death or other major events.
Conclusions
Changes over time or absolute values in the chronic phase of both markers were not associated with clinical outcomes. CRP levels, but not MPO levels, in the index event were predictive of long‐term cardiovascular mortality. Copyright © 2009 Wiley Periodicals, Inc.
Keywords: inflammation, unstable angina, myocardial infarction, prognosis, markers
Full Text
The Full Text of this article is available as a PDF (428.2 KB).
References
- 1. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 1999;340:115–126. [DOI] [PubMed] [Google Scholar]
- 2. Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation 2005;111:3481–3488. [DOI] [PubMed] [Google Scholar]
- 3. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ: Atherothrombosis and high‐risk plaque. J Am Coll Cardiol 2005;46:937–954. [DOI] [PubMed] [Google Scholar]
- 4. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, et al.: C‐reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A sub‐study. J Am Coll Cardiol 1998;31:1460–1465. [DOI] [PubMed] [Google Scholar]
- 5. Ridker PM, Glynn RJ, Hennekens CH: C‐reactive protein adds to the predictive value of total and HDL‐cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007–2011. [DOI] [PubMed] [Google Scholar]
- 6. James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, et al.: Troponin and C‐reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndromes. A GUSTO‐IV substudy. J Am Coll Cardiol 2003;41:916–924. [DOI] [PubMed] [Google Scholar]
- 7. Oltrona L, Ottani F, Galvani M: Clinical significance of a single measurement of troponin‐I and C‐reactive protein at admission in 1773 consecutive patients with acute coronary syndromes. Am Heart J 2004;148:405–415. [DOI] [PubMed] [Google Scholar]
- 8. Manenti ER, Bodanese LC, Camey SA, Polanczyk CA: Prognostic value of serum biomarkers in association with TIMI risk score for acute coronary syndromes. Clin Cardiol 2006;29:405–410. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, et al.: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440–1445. [DOI] [PubMed] [Google Scholar]
- 10. Polanczyk CA, Schneid S, Imhof BV, Furtado M, Pithan C, et al.: Impact of redefining acute myocardial infarction on incidence, management and reimbursement rate of acute coronary syndromes. Int J Cardiol 2006;107:180–187. [DOI] [PubMed] [Google Scholar]
- 11. Heeschen C, Hamm CW, Bruemmer J, Simoons ML: Predictive value of C‐reactive protein and troponin T in patients with unstable angina: A comparative analysis. CAPTURE Investigators. Chimeric C7e3 antiplatet therapy in unstable angina refractory to standard treatment trial. J Am Coll Cardiol 2000;35:1535–1542. [DOI] [PubMed] [Google Scholar]
- 12. Lindhal B, Toss H, Siegbahn A, Venge P, Wallentin L: Markers of myocardial damage and inflammation in relation to long‐term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139–1147. [DOI] [PubMed] [Google Scholar]
- 13. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, et al.; on the Behalf of the Committee on Standardization of Markers of Cardiac Damage of the IFCC: Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51:810–824. [DOI] [PubMed] [Google Scholar]
- 14. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, et al.: Markers of inflammation and cardiovascular disease: Application to clinical and public heath practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511. [DOI] [PubMed] [Google Scholar]
- 15. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, et al.: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595–1604. [DOI] [PubMed] [Google Scholar]
- 16. Esporcatte R, Rey HCV, Rangel FOD, Rocha RM, Mendonça HTF, et al.: Predictive value of myeloperoxidase to identify high risk patients admitted to the hospital with acute chest pain. Arq Bras Cardiol 2007;89(6):377–384. [DOI] [PubMed] [Google Scholar]
- 17. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, et al.: Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007;49:1993–2000. [DOI] [PubMed] [Google Scholar]
- 18. Chang PY, Wu TL, Hung CC, Tsao KC, Sun CF, et al.: Development of an ELISA for myeloperoxidase on microplate: Normal reference values and effect of temperature on specimen preparation. Clin Chim Acta 2006;373:158–163. [DOI] [PubMed] [Google Scholar]
- 19. Blake GJ, Ridker PM: C‐reactive protein and other inflammatory risk markers in acute coronary syndrome. J Am Coll Cardiol 2003;41:37S–42S. [DOI] [PubMed] [Google Scholar]
- 20. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, et al.: Statin therapy, LDL cholesterol, C‐reactive protein, and coronary artery disease. N Engl J Med 2005;352:29–38. [DOI] [PubMed] [Google Scholar]
- 21. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, et al.: C‐reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20–28. [DOI] [PubMed] [Google Scholar]